Literature DB >> 8592943

Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone.

R A Dodds1, J R Connor, I E James, E L Rykaczewski, E Appelbaum, E Dul, M Gowen.   

Abstract

Osteopontin is a phosphorylated glycoprotein believed to be secreted by osteoblasts and deposited into the bone matrix to facilitate osteoclasts adhesion or to initiate osteoid mineralization. Previously we have presented contradictory evidence that osteoclasts express osteopontin mRNA in human remodeling bone. The aim of this study was to ascertain whether osteoclasts synthesize and deposit osteopontin in resorption lucunae. We characterized expression of osteopontin mRNA and protein expression in both intramembranous and endochondral ossification, as well as remodeling bone, in the human osteophyte. Osteopontin mRNA was expressed in osteoclast with tartrate-resistant acid phosphatase (TRAP) positivity within resorption lacunae. The osteoclasts and immediate resorption surfaces also expressed osteopontin. However, osteopontin mRNA and protein were weak (transient) or undetectable in osteoblasts at adjacent bone formation sites; no osteopontin expression was observed in the osteoid, although occasional reactivity was observed in osteocytes and the mineral-osteoid interface. In contrast, osteopontin was highly expressed in the osteoblasts and matrix of woven bone during intramembranous and endochondral ossification. The matrix expression correlated with mineralization; however, in some instances osteopontin deposition was observed prior to mineralization. Similarly, osteopontin expression was evident in cartilage matrix, solely at foci of mineralization. Chondroclasts expressed osteopontin mRNA and protein: the surfaces of resorbed calcified cartilage also expressed osteopontin. Abnormal, unmineralized matrices apparently lacked deposited osteopontin, but were nevertheless resorbed by osteoclasts; the osteoclasts and resorbed surfaces expressed no osteopontin protein. That osteoclasts are responsible for the deposition of osteopontin was confirmed in vitro, whereby resorption pits in whale dentine and bovine bone slices, produced by isolated human osteoclasts, contained deposited osteopontin. Osteopontin may facilitate the adhesion (or detachment) of the osteoclast to the bone surface. Alternatively, the possibility that osteopontin may act as a postresorptive signal to recruit osteoblasts, or to polarize and direct the mineralization of the formed osteoid, is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592943     DOI: 10.1002/jbmr.5650101109

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  32 in total

1.  In vitro expression of proalpha1(I) collagen mRNA by human pre-osteoclastic cells.

Authors:  L Masi; C Malentacchi; S Benvenuti; A Amedei; U Bigozzi; E Montali; M L Brandi
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

Review 2.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Distribution of matrix metalloproteinases and their inhibitor, TIMP-1, in developing human osteophytic bone.

Authors:  S Bord; A Horner; R M Hembry; J J Reynolds; J E Compston
Journal:  J Anat       Date:  1997-07       Impact factor: 2.610

Review 4.  Bone matrix proteins: their function, regulation, and relationship to osteoporosis.

Authors:  Marian F Young
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

5.  Bio-Oss®acts on Stem cells derived from Peripheral Blood.

Authors:  Vincenzo Sollazzo; Annalisa Palmieri; Luca Scapoli; Marcella Martinelli; Ambra Girardi; Francesco Alviano; Agnese Pellati; Vittoria Perrotti; Francesco Carinci
Journal:  Oman Med J       Date:  2010-01

6.  Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.

Authors:  Tajneen Natasha; Misty Kuhn; Owen Kelly; Susan R Rittling
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

7.  Anti-cytokine autoantibodies in autoimmune diseases.

Authors:  Giuseppe Cappellano; Elisabetta Orilieri; Abiy D Woldetsadik; Elena Boggio; Maria F Soluri; Cristoforo Comi; Daniele Sblattero; Annalisa Chiocchetti; Umberto Dianzani
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

8.  Histologic evaluation of human alveolar sockets treated with an artificial bone substitute material.

Authors:  Mari Wakimoto; Takaaki Ueno; Azumi Hirata; Seiji Iida; Tara Aghaloo; Peter K Moy
Journal:  J Craniofac Surg       Date:  2011-03       Impact factor: 1.046

9.  Mechanical properties and osteocompatibility of novel biodegradable alanine based polyphosphazenes: Side group effects.

Authors:  Swaminathan Sethuraman; Lakshmi S Nair; Saadiq El-Amin; My-Tien Nguyen; Anurima Singh; Nick Krogman; Yaser E Greish; Harry R Allcock; Paul W Brown; Cato T Laurencin
Journal:  Acta Biomater       Date:  2009-12-24       Impact factor: 8.947

Review 10.  Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

Authors:  T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.